CoChat

A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy

Open access

Published version of a preprint

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

PURPOSE: Development of a supervised machine-learning model capable of predicting clinically relevant molecular subtypes of pancreatic ductal adenocarcinoma (PDAC) from diffusion-weighted-imaging-derived radiomic features. METHODS: The retrospective observational study assessed 55 surgical PDAC patients. Molecular subtypes were defined by immunohistochemical staining of KRT81. Tumors were manually segmented and 1606 radiomic features were extracted with PyRadiomics. A gradient-boosted-tree algorithm was trained on 70% of the patients (N = 28) and tested on 30% (N = 17) to predict KRT81+ vs. KRT81- tumor subtypes. A gradient-boosted survival regression model was fit to the disease-free and overall survival data. Chemotherapy response and survival were assessed stratified by subtype and radiomic signature. Radiomic feature importance was ranked. RESULTS: The mean±STDEV sensitivity, specificity and ROC-AUC were 0.90±0.07, 0.92±0.11, and 0.93±0.07, respectively. The mean±STDEV concordance indices between the disease-free and overall survival predicted by the model based on the radiomic parameters and actual patient survival were 0.76±0.05 and 0.71±0.06, respectively. Patients with a KRT81+ subtype experienced significantly diminished median overall survival compared to KRT81- patients (7.0 vs. 22.6 months, HR 4.03, log-rank-test P = <0.001) and a significantly improved response to gemcitabine-based chemotherapy over FOLFIRINOX (10.14 vs. 3.8 months median overall survival, HR 2.33, P = 0.037) compared to KRT81- patients, who responded significantly better to FOLFIRINOX over gemcitabine-based treatment (30.8 vs. 13.4 months median overall survival, HR 2.41, P = 0.027). Entropy was ranked as the most important radiomic feature. CONCLUSIONS: The machine-learning based analysis of radiomic features enables the prediction of subtypes of PDAC, which are highly relevant for disease-free and overall patient survival and response to chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0218642

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 Histopathological samples of two patients showing comparable tissue morphology in H&E staining (A,C) but a KRT81+ subtype (B) in one patient and KRT81- subtype (D) in the other patient.
Fig 1 Histopathological samples of two patients showing comparable tissue morphology in H&E staining (A,C) but a KRT81+ subtype (B) in one patient and KRT81- subtype (D) in the other patient.CC BY · PubMed Central
Fig 2 Patients with a KRT81+ subtype experienced significantly diminished overall survival.
Fig 2 Patients with a KRT81+ subtype experienced significantly diminished overall survival.CC BY · PubMed Central
Fig 3 ROC curves (colored) and average ROC-curve (black dotted) over 10 random stratified shuffle-splits of the dataset.
Fig 3 ROC curves (colored) and average ROC-curve (black dotted) over 10 random stratified shuffle-splits of the dataset.CC BY · PubMed Central
Fig 4 Exemplary Kaplan-Meier disease-free survival curve drawn from the 10 cross-validation folds representing the median hazard ratio. Patients with a high risk radiomic phenotype experienced significantly diminished survival (7.90 vs. 24.20 months median DFS, log-rank-test p = 0.004, HR = 3.17, N = 17).
Fig 4 Exemplary Kaplan-Meier disease-free survival curve drawn from the 10 cross-validation folds representing the median hazard ratio. Patients with a high risk radiomic phenotype experienced significantly diminished survival (7.90 vs. 24.20 months median DFS, log-rank-test p = 0.004, HR = 3.17, N = 17).CC BY · PubMed Central
Fig 5 Exemplary Kaplan-Meier overall survival curve drawn from the 10 cross-validation folds representing the median hazard ratio. Patients with a high risk radiomic phenotype experienced significantly diminished survival (10.97 vs. 25.70 months median OS, log-rank-test p = 0.006, HR = 3.03, N = 17).
Fig 5 Exemplary Kaplan-Meier overall survival curve drawn from the 10 cross-validation folds representing the median hazard ratio. Patients with a high risk radiomic phenotype experienced significantly diminished survival (10.97 vs. 25.70 months median OS, log-rank-test p = 0.006, HR = 3.03, N = 17).CC BY · PubMed Central
Fig 6 Exemplary Kaplan-Meier plot of patients with a predicted KRT81+/ high risk radiomic signature drawn from the 10 cross-validation folds and representing the median hazard ratio. Patients who received gemcitabine experienced improved survival, although no statistical significance is observed in this case (median survival 4.70 vs 9.30 months, p = 0.23, HR = 1.03, N = 7).
Fig 6 Exemplary Kaplan-Meier plot of patients with a predicted KRT81+/ high risk radiomic signature drawn from the 10 cross-validation folds and representing the median hazard ratio. Patients who received gemcitabine experienced improved survival, although no statistical significance is observed in this case (median survival 4.70 vs 9.30 months, p = 0.23, HR = 1.03, N = 7).CC BY · PubMed Central
Fig 7 Exemplary Kaplan-Meier plot of patients with a predicted KRT81-/ low risk radiomic signature drawn from the 10 cross-validation folds and representing the median hazard ratio. Patients who received FOLFIRINOX experienced significantly improved survival, (median survival 17.83 vs 30.10 months, p = 0.01, HR = 2.57, N = 10).
Fig 7 Exemplary Kaplan-Meier plot of patients with a predicted KRT81-/ low risk radiomic signature drawn from the 10 cross-validation folds and representing the median hazard ratio. Patients who received FOLFIRINOX experienced significantly improved survival, (median survival 17.83 vs 30.10 months, p = 0.01, HR = 2.57, N = 10).CC BY · PubMed Central
Fig 8 Patients with KRT81+ subtype experience longer overall survival under palliative gemcitabine chemotherapy.
Fig 8 Patients with KRT81+ subtype experience longer overall survival under palliative gemcitabine chemotherapy.CC BY · PubMed Central
Fig 9 Patients with KRT81- subtype experience improved survival under palliative FOLFIRINOX chemotherapy.
Fig 9 Patients with KRT81- subtype experience improved survival under palliative FOLFIRINOX chemotherapy.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 76

Metadata

Authors
Kaissis, G., Ziegelmayer, S., Lohöfer, F., Steiger, K., Algül, H., Muckenhuber, A., Yen, H.-Y., Rummeny, E., Friess, H., Schmid, R., Weichert, W., Siveke, J. T., & Braren, R.
Affiliations
  • Technical University of Munich (DE)
  • German Cancer Research Center (DE)
Corresponding author
Braren, Rickmer
Venue
PLOS ONE
Published
2019-10-02
Volume
14
Issue
10
Pages
e0218642
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2979283201
Cited by
76
References
40
Citations by year
2025: 7 · 2024: 9 · 2023: 13 · 2022: 7 · 2021: 20 · 2020: 14 · 2019: 3
FWCI
7.26
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • mediaTUM (Technical University of Munich) (submittedVersion)
Funders
Deutsche Forschungsgemeinschaft (SFB284 Project C6, SFB824/Project Z2)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
Keywords
pancreatic ductal adenocarcinoma, molecular subtypes, radiomics, diffusion-weighted imaging, gemcitabine-based chemotherapy, FOLFIRINOX, chemotherapy response prediction, survival prediction, gradient boosting decision tree, entropy, PyRadiomics, immunohistochemistry, machine learning prediction models, overall survival, disease-free survival
MeSH terms
Machine Learning, Irinotecan, Oxaliplatin, Gemcitabine, Adult, Antineoplastic Combined Chemotherapy Protocols, Leucovorin, Deoxycytidine, Female, Fluorouracil, Humans, Male, Middle Aged, Neoplasm Proteins, Pancreatic Neoplasms, Retrospective Studies, Sensitivity and Specificity, Survival Rate, Disease-Free Survival, Carcinoma, Pancreatic Ductal, Keratins, Type II, Keratins, Hair-Specific

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy. https://app.cochat.ai/papers/10.1371/journal.pone.0218642
The paper
Kaissis, G., Ziegelmayer, S., Lohöfer, F., Steiger, K., Algül, H., Muckenhuber, A., Yen, H.-Y., Rummeny, E., Friess, H., Schmid, R., Weichert, W., Siveke, J. T., & Braren, R. (2019). A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy. PLOS ONE. https://doi.org/10.1371/journal.pone.0218642

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.